|
|
|
| The Function of Long Noncoding RNA Gene MEG3 in Tumorigenesis, Development and Diagnosis |
| LIU Xiao-Qian1, DONG Yan-Qiu1, JIN Lan-Jie1, LI Dong-Jie2, LI Shi-Jie1,* |
1 College of Life Science, Hebei Agricultural University, Baoding 071001, China;
2 College of Bioscience and Bioengineering, Hebei University of Science and Technology, Shijiazhuang 050018, China |
|
|
|
|
Abstract Long non-coding RNAs (lncRNAs) are now considered as central regulators in normal biological activites and critically involved in the tumorigenesis. The maternally expressed gene 3 (MEG3) is located in DLK1-DIO3 imprinted region on human chromosome 14q32.2. MEG3 gene is composed of 34.9 kb size and encodes an approximately 1.6 kb lncRNA. The MEG3 is either lost or down-regulated in a many primary human tumors and tumors derived cell lines, and exhibits the function of tumor suppressor. MEG3 controls the expression of some tumor suppressor genes and oncogenes, such as p53, RB, MYC and TGF-β. MEG3 also affects epithelial-mesenchymal transition through regulating the Wnt-β-catenin signaling pathway. In addition, the methylation modification and polymorphic sites within the MEG3 locus are also associated with cancer risk of and drug therapeutic response of patients. In this review, several aspects of MEG3 participating in tumorigenesis, and the potential value in cancer diagnosis and prognosis are discussed. This article provides a basis for the follow-up study of the role of MEG3 in human tumor therapy.
|
|
Received: 08 March 2021
|
|
|
|
Corresponding Authors:
* lishijie20005@163.com
|
|
|
|
[1] 王建春, 李冬杰, 杜卫华, 等. 2008. GTL2基因在体细胞核移植牛中的印记状态分析, 生物化学与生物物理进展, 35(10): 1183~1187.
(Wang J C, Li D J, Du W H, et al. 2008. Genomic imprinting of GTL2 in somatic cell nuclear transfer cattle (in Chinese)[J]. Progress in Biochemistry and Biophysics, 35(10): 1183~1187.)
[2] 杨文志, 张萃, 王冠楠, 等. 2016. 基因组印记中的长非编码RNA[J]. 生物化学与生物物理进展, 43(05): 461-471.
(Yang W Z, Zhang C, Wang G N, et al. 2016. The Function of long non-coding RNAS in genomic imprinting[J], Progress in Biochemistry and Biophysics, 43(05):461-471.)
[3] 张萃, 陈玮娜, 李俊良, 等. 2019. LINC24065在体细胞核移植牛中的异常表达.畜牧兽医学报. 50(1):44-51.
(Zhang C, Chen W N, Li J L, et al. 2019. Abnormal expression of LINC24065 in somatic cell nuclear transfer cattle. Acta Veterinaria et Zootechnica Sinica, 50(1):44-51)
[4] Astuti D, Latif F, Wagner K, et al.2005. Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: Analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour[J]. British Journal of Cancer, 92(8): 1574-1580.
[5] Benetatos L, Dasoula A, Hatzimichael E, et al.2008. Promoter hypermethylation of the MEG3 (DLK1/MEG3) imprinted gene in multiple myeloma[J]. Clinical Lymphoma Myeloma & Leukemia, 8(3): 171-175.
[6] Benetatos L, Hatzimichael E, Dasoula A, et al.2010. CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes[J]. Leukemia Research, 34(2): 148-153.
[7] Benetatos L, Vartholomatos G, Hatzimichael E.2011. MEG3 imprinted gene contribution in tumorigenesis[J]. International Journal of Cancer, 129(4): 773-779.
[8] Binabaj M M, Bahrami A, Bahreyni A, et al.2018. The prognostic value of long noncoding RNA MEG3 expression in the survival ofpatients with cancer: A meta-analysis[J]. Journal of Cellular Biochemistry, 119(11): 9583-9590.
[9] Cao Y, Dishihara R, Qian Z R, et al.2016. Regular aspirin use associates with lower risk of colorectal cancers with low numbers of tumor-infiltrating lymphocytes[J]. Gastroenterology, 151(5): 879-892.
[10] Fatima R, Akhade V S, Pal D, et al.2015. Long noncoding RNAs in development and cancer: potential biomarkers and therapeutic targets[J]. Molecular & Cellular Therapies, 3(1): 5.
[11] Follis A V, Llambi F, Ou L, et al.2014. The DNA-binding domain mediates both nuclear and cytosolic functions of p53[J]. Nature Structural & Molecular Biology, 21(6): 535-543.
[12] Gejman R, Batista D L, Zhong Y, et al.2008. Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas[J]. Journal of Clininal Endocrinology & Metabolism, 93(10): 4119-4125.
[13] Giacinti C, Giordano A.2006. RB and cell cycle progression[J]. Oncogene, 25(38): 5220-5227.
[14] Greife A, Knievel J, Ribarska T, et al.2014. Concomitant downregulation of the imprinted genes DLK1 and MEG3 at 14q32.2 by epigenetic mechanisms in urothelial carcinoma[J]. Clinical Epigenetics, 6(1): 29.
[15] Haupt S, Haupt Y.2017. P53 at the start of the 21st century: Lessons from elephants[J]. F1000Researsh, 6: 2041.
[16] He J H, Han Z P, Liu J M, et al.2017. Overexpression of long non-coding RNA MEG3 inhibits proliferation of hepatocellular carcinoma Huh7 cells via negative modulation of miRNA-664[J]. Journal of Cellular Biochemistry, 118(11): 3713-3721.
[17] Hou Y W, Zhang B, Miao L M, et al.2019. Association of long non-coding RNA MEG3 polymorphisms with oral squamous cell carcinoma risk[J]. Oral Diseases, 25(5): 1318-1324.
[18] Jin L Y, Cai Q, Wang S H, et al.2018. Long noncoding RNA MEG3 regulates LATS2 by promoting the ubiquitination of EZH2 and inhibits proliferation and invasion in gallbladder cancer[J]. Cell Death & Disease, 9(10): 1017.
[19] Jung H S, Vallee S E, Dinulos M B, et al.2018. Maternally inherited 133kb deletion of 14q32 causing Kagami-Ogata syndrome[J]. Journal of Human Genetics, 63(12): 1231-1239.
[20] Laursen L.2014. A preventable cancer[J]. Nature, 516(7529): S2-S3.
[21] Li Z Y, Li C Z, Liu C H, et al.2014. Expression of the long non-coding RNAs MEG3, HOTAIR, and MALAT-1 in non-functioning pituitary adenomas and their relationship to tumor behavior[J]. Pituitary, 18(1): 42-47.
[22] Liu H, Ye D, Chen A, et al.2019. A pilot study of new promising non-coding RNA diagnostic biomarkers for early-stage colorectal cancers[J]. Clinical Chemistry and Laboratory Medicine, 57(7): 1073-1083.
[23] Liu J, Wan L, Lu K, et al.2015. The long noncoding RNA MEG3 contributes to cisplatin resistance of human lung adenocarcinoma[J]. PLoS One, 10(5): e0114586.
[24] Lu K H, Li W, Liu X H, et al.2013. Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression[J]. BMC Cancer, 13: 461.
[25] Malek E, Jagannathan S, Driscoll J J.2014. Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer[J]. Oncotarget, 5(18): 8027-8038.
[26] Manfredi J J.2010. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor[J]. Genes & Development, 24(15):1580-1589.
[27] Masayo K, Keisuke N, Rika K, et al.2017. Temple syndrome: Comprehensive molecular and clinical findings in 32 Japanese patients[J]. Genetics in Medicine. 19(12): 1356-1366.
[28] Mondal T, Subhash S, Vaid R, et al.2015. MEG3 long noncoding RNA regulates the TGF-beta pathwaygenes throughformation of RNA-DNA triplex structures[J]. Nature Communications, 6: 7743.
[29] Peng W Z, Si S, Zhang Q, et al.2015. Long non-coding RNA MEG3 functions as a competing endogenous RNA to regulate gastric cancer progression[J]. Journal of Experimental & Clinical Cancer, 34(1): 79.
[30] Petitjean A, Mathe E, Kato S, et al.2007. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database[J]. Human Mutation, 28(6): 622-629.
[31] Qin R, Chen Z, Ding Y, et al.2013. Long noncoding RNA MEG3 inhibits the proliferation of cervical carcinoma cells through the induction of cell cycle arrest and apoptosis[J]. Neoplasma, 60(5): 486-492.
[32] Ricciuti B, Mencaroni C, Paglialunga L, et al.2016. Long noncoding RNAs: New insights into non-small cell lung cancer biology, diagnosis and therapy[J]. Medical Oncology, 33(2): 18.
[33] Riley T, Sontag E, Chen P, et al.2008. Transcriptional control of human p53-regulated genes[J]. Nature Reviews Molecular Cell Biology, 9(5): 402-412.
[34] Su H, Li D J, Hou X H, et al.2011. Molecular structure of bovine Gtl2 gene and DNA methylation status of Dlk1-Gtl2 imprinted domain in cloned bovines[J]. Animal Reproduction Science, 127(1-2): 23~30.
[35] Sun L, Li Y, Yang B.2016. Down regulated longnon-codingRNA MEG3 in breast cancer regulates proliferation, migration and invasion by depending on p53's transcriptional activity[J]. Biochemical Biophys & Research Communications, 478(1): 323-329.
[36] Sun M, Xia R, Jin F, et al.2014. Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer[J]. Tumor Biology, 35(2): 1065-1073.
[37] Terashima M, Tange S, Ishimura A, et al.2017. MEG3 Longnoncoding RNA contributes to the epigenetic regulation of epithelial-mesenchymal transition in lung cancer cell lines[J]. Journal of Biology Chemistry. 292(1): 82-99.
[38] Tian Z Z, Guo X J, ZhaoY M, et al.2015. Decreased expression of long non-coding RNA MEG3 acts as a potential predictor biomarker in progression and poor prognosis of osteosarcoma[J]. International Journal of Clinical and Experimental PathologyInt, 8(11): 15138-15142.
[39] Tsai M C, Spitale R C, Chang H Y.2011. Long intergenic noncoding RNAs: New links in cancer progression[J]. Cancer Research, 71(1): 3-7.
[40] Uroda T, Anastasakou E, Rossi A, et al.2019. Conserved pseudoknots in lncRNA MEG3 are essential for stimulation of the p53 pathway[J]. Molecular Cell, 75(5): 982-995.
[41] Wang P, Ren Z, Sun P.2012. Overexpression of the long noncoding RNA MEG3 impairs in vitro glioma cell proliferation[J]. Journal of Cellular Biochemistry, 113(6): 1868-1874.
[42] Wang Y, Guo Z, Zhao Y, et al.2017. Genetic polymorphisms of lncRNA-p53 regulatory network genes are associated with concurrent chemoradiotherapy toxicities and efficacy in nasopharyngeal carcinoma patients[J]. Scientific Reports, 7(1): 8320.
[43] Yang Z, Li H, Li J, et al.2018. Association between long noncoding RNA MEG3 polymorphisms and lung cancer susceptibility in Chinese northeast population[J]. DNA and Cell Biology, 37(10): 812-820.
[44] Yin D, Liu Z, Zhang E, et al.2015. Decreased expression of long noncoding RNA MEG3 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer[J]. Tumour Biology. 36(6): 4851-4859.
[45] Zhang J, Yao T, Lin Z, et al.2017. Aberrant methylation of MEG3 functions as a potential plasma-based biomarker for cervical cancer[J]. Scientific Reports, 7(1): 6271.
[46] Zhang X, Rice K, Wang Y, et al.2010. Maternally expressed gene 3 (MEG3) noncoding ribonucleic acid: Isoform structure, expression, and functions[J]. Endocrinology, 151(3): 939-947.
[47] Zhang J, Yao T,Wang Y, et al.2016. Long noncoding RNA MEG3 is downregulated in cervical cancer and affects cell proliferation and apoptosis by regulating miR-21[J]. Cancer Biology & Therapy, 17(1): 104-113.
[48] Zhang X, Sun H, Danila D C, et al.2002. Loss of expression of GADD45 gamma, a growth inhibitory gene, in human pituitary adenomas: Implications for tumorigenesis[J]. Journal of Clinical Endocrinology & Metabolism, 87(3): 1262-1267.
[49] Zhang Z, Li M, Wang H, et al.2003. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy[J]. Proceedings of the National Academy of Sciences of the USA, 100(20): 11636-11641.
[50] Zhao H, Wang X, Feng X, et al.2018. Long non-coding RNA MEG3 regulates proliferation, apoptosis, and autophagy and is associated with prognosis in glioma[J]. Journal of Neuro-oncology, 140(2): 281-288.
[51] Zheng Q, Lin Z, Xu J, et al.2018. Long noncoding RNA MEG3 suppresses liver cancer cells growth through inhibiting β-catenin by activating PKM2 and inactivating PTEN[J]. Cell Death & Disease, 9(3): 253.
[52] Zhou Y, Zhong Y, Wang Y, et al.2007. Activation of p53 by MEG3 non-coding RNA[J]. Journal of Biological Chemistry, 282(34): 24731-24742.
[53] Zhu Y, Chen P, Gao Y,et al.2018. MEG3 activated by vitamin D inhibits colorectal cancer cells proliferation and migration via regulating Clusterin[J]. EBioMedicine, 30: 148-157.
[54] Zhuo Z J, Zhang R, Zhang J, et al.2018. Associations between lncRNA MEG3 polymorphisms and neuroblastoma risk in Chinese children[J]. Aging. 10(3): 481-491.
[55] Zilfou J T, Lowe S W.2009. Tumor suppressive functions of p53[J]. Cold Spring Harbor Perspectives in Biology, 1(5): a001883. |
|
|
|
